Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03195010 · ClinicalTrials.gov registry record · Phase 2

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.

Terminated
Registry status
Phase 2
Development phase
4
Enrollment target

NCT03195010 is a Phase 2 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03195010, a Phase 2 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.

TERMINATED
Registry status
Phase 2
Development phase
4 participants
Enrollment target

Study Summary

This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood thinners) for blood clots. Giving relatively fewer platelet transfusions may reduce the side effects of frequent platelet transfusions without leading to undue bleeding.

Interventions

  • BIOLOGICAL Platelet Transfusion

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2017-06-09
Est. Completion 2018-12-21
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT03195010

The ClinicalTrials.gov registry entry for NCT03195010 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Platelet Transfusion is the first listed.

NCT03195010 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03195010 about?

NCT03195010 is a clinical study titled "Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia". This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood thinners) for blood clots. Giving relatively fewer platelet transfusions ma...

What is the current status of trial NCT03195010?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-06-09. Estimated completion is 2018-12-21.

What interventions are being tested in trial NCT03195010?

The interventions under investigation include: Platelet Transfusion (BIOLOGICAL).

Who is sponsoring clinical trial NCT03195010?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.